{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-22-000020","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.465534+00:00","generated_at":"2026-06-25T23:17:16.751430+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"BioMarin appoints Erin Burkhart as Chief Accounting Officer","bullets":["Burkhart named Group VP, CAO effective May 2, 2022; succeeds Brian Mueller who remains CFO and principal financial officer.","Burkhart joins from Eli Lilly where she held senior roles; CPA with public accounting background at Arthur Andersen and Deloitte.","Compensation includes $400K salary, 45% cash incentive target, $250K sign-on bonus, $250K relocation bonus, and $1.5M equity awards (RSUs + options).","Equity grants under 2017 Equity Incentive Plan; RSUs vest 25% annually, options vest monthly over 4 years with 1-year cliff."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-22-000020","json":"https://secwatch.observer/filing/0001048477-22-000020.json","markdown":"https://secwatch.observer/filing/0001048477-22-000020.md","text":"https://secwatch.observer/filing/0001048477-22-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847722000020/0001048477-22-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847722000020/bmrn-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:17:16.751430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"daa5b74144","claim":"Erin Burkhart was appointed as Group Vice President, Chief Accounting Officer at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"On May 05, 2022., BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) announced the appointment of Erin Burkhart as BioMarin’s Group Vice President, Chief Accounting Officer, effective May 2, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847722000020/0001048477-22-000020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Group Vice President, Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}